Debut Plus

₹1,452.9

▼ -27.99 -1.89%

17 Jul 2026

NSE Listed

Senores Pharmaceuticals Limited (SENORES)

Volume: 2,40,001Avg Vol 1W: 2,25,772.8Avg Vol 1M: 3,47,775.8552W Range:₹601.1₹1,509.8
NSE BSE www.senorespharma.com
Key Ratios
Checked just now
Market Cap₹6,691 Cr
Current Price₹1,452.9
Previous Close₹1,480.89
High / Low (52w)₹1,509.8 / ₹601.1
Volume2,40,001
Avg Vol (1W)2,25,772.8
Avg Vol (1M)3,47,775.85
Stock P/E182.53
Book Value₹202.72
Dividend Yield0%
ROE12.36%
ROA7.58%
Revenue (TTM)₹418 Cr
Revenue Growth85.7%
Profit Margin18.32%
Total Debt₹162 Cr
Shares Outstanding5 Cr
Face Value₹10
EPS (TTM)₹25.05
P/B7.17
Debt / Equity0.58
50 DMA₹1,239.15
200 DMA₹910.24
Day change-1.89%
Price Chart
₹1,452.9▲ 133.51% · 1Y
₹1481₹60977.5L
2025-07-17
2026-07-16

20-day avg volume: 3.5L shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 45% YoY.
  • Stock trades at a high P/E of 183.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹80 Cr₹101 Cr₹103 Cr₹114 Cr₹138 Cr₹162 Cr₹171 Cr₹175 Cr
EBITDA₹18 Cr₹21 Cr₹27 Cr₹26 Cr₹32 Cr₹47 Cr₹50 Cr₹56 Cr
Net Profit₹11 Cr₹13 Cr₹17 Cr₹18 Cr₹20 Cr₹32 Cr₹32 Cr₹32 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹8 Cr₹15 Cr₹39 Cr₹217 Cr₹418 Cr
EBITDA₹1 Cr₹2 Cr₹15 Cr₹34 Cr₹92 Cr
Net Profit₹1 Cr₹1 Cr₹8 Cr₹31 Cr₹59 Cr
EPS4.071.816.6512.2116.12
Balance Sheet
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹15 Cr₹59 Cr₹131 Cr₹622 Cr₹1,227 Cr
Total Liabilities₹5 Cr₹23 Cr₹86 Cr₹390 Cr₹415 Cr
Equity₹9 Cr₹37 Cr₹45 Cr₹232 Cr₹812 Cr
Total Debt₹3 Cr————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹-3 Cr₹-10 Cr₹0 Cr₹-23 Cr₹-37 Cr
Investing₹-4 Cr₹-24 Cr₹-48 Cr₹-54 Cr₹-429 Cr
Financing₹8 Cr₹36 Cr₹46 Cr₹87 Cr₹573 Cr
Free Cash Flow₹-6 Cr₹-10 Cr₹0 Cr₹-23 Cr₹-37 Cr
Shareholding
Promoter 45.82% Institutions 13.25% Public 40.93%
Efficiency & Working Capital
ROCE14.4%
Interest Coverage4.3
Dividend Payout—
Debtor Days114 d
Inventory Days52 d
Payable Days62 d
Cash Conversion Cycle104 d
Working Capital Days165 d
Shareholding Details

As of 2026-03-31

Promoter45.8%
FII3.6%
DII9.6%
Institutions13.3%
Public40.9%
Promoter Pledge1.9%
No. of Shareholders34,126
Shareholding Pattern

Quarterly — figures in %. Latest 9 quarters.

PeriodJul 2024Jul 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Promoters66.7%66.7%45.8%45.8%45.8%45.8%45.8%45.8%45.8%
FIIs0%0%5.5%4.3%4.2%3.7%4.3%3.3%3.6%
DIIs33.3%0%18.6%11.8%9.7%9.5%8.6%9.3%9.6%
Public0%33.3%30.1%38.2%40.4%41%41.3%41.5%40.9%
Promoter Pledge0%0%0%0%0%0%0%1.9%1.9%
No. of Shareholders17717743,70749,51837,65336,38934,91734,40134,126
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Swapnil Jatin ShahShareholding of Promoter and Promoter Group7.7%35,53,531
Ashokbhai Vijaysinh BarotShareholding of Promoter and Promoter Group7.5%34,44,869
Remus Pharmaceuticals LimitedShareholding of Promoter and Promoter Group7.1%32,61,744
Renosen Pharmaceuticals Private LimitedShareholding of Promoter and Promoter Group5.9%27,18,719
Anar Swapnil ShahShareholding of Promoter and Promoter Group5%22,94,500
Aviraj Overseas LlcShareholding of Promoter and Promoter Group4.1%18,95,190
Aditya Birla Sun Life Insurance Company LimitedPublic Shareholding3%13,63,254
Hsbc Mutual Fund - Hsbc Value FundPublic Shareholding2.3%10,55,025
Sangeeta Mukur BarotShareholding of Promoter and Promoter Group2.3%10,42,955
Manoj Prakash SanghviPublic Shareholding1.9%8,54,484
Ratnamani Marketing Private LimitedPublic Shareholding1.8%8,38,000
Astorne Capital Vcc - ArvenPublic Shareholding1.5%7,05,346
Aviraj Group LlcShareholding of Promoter and Promoter Group1.5%6,84,750
Mahindra Manulife Large & Mid Cap FundPublic Shareholding1.4%6,47,000
Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) FundPublic Shareholding1.4%6,32,670
Jayanti Mishrimal Sanghvi .Public Shareholding1.2%5,67,823
Jigar Prakash SanghviPublic Shareholding1.2%5,49,523
Espee Therapeutics LlpShareholding of Promoter and Promoter Group1.1%4,95,000
Jitendra Babulal SanghviShareholding of Promoter and Promoter Group1.1%4,88,516
Prakash Mishrimal SanghviPublic Shareholding1%4,76,190
Mukur Yogeshkumar BarotShareholding of Promoter and Promoter Group1%4,56,825
Shantaben Babulal SanghviShareholding of Promoter and Promoter Group0.7%3,28,569
Dhananjay Ashokkumar BarotShareholding of Promoter and Promoter Group0.7%3,12,689
Hemant Ishwarlal ModiShareholding of Promoter and Promoter Group0.1%62,000
Pinky Jatin ShahShareholding of Promoter and Promoter Group0.1%30,500
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Swapnil Jatin Shah00%2026-03-31
Ashokbhai Vijaysinh Barot00%2026-03-31
Anar Swapnil Shah00%2026-03-31
Sangeeta Mukur Barot00%2026-03-31
Jitendra Babulal Sanghvi00%2026-03-31
Mukur Yogeshkumar Barot00%2026-03-31
Shantaben Babulal Sanghvi00%2026-03-31
Hemant Ishwarlal Modi00%2026-03-31
Pinky Jatin Shah00%2026-03-31
Jatin Siddharthbhai Shah00%2026-03-31
Rajendra Brahmbhatt00%2026-03-31
Bhavna Barot00%2026-03-31
Board of Directors
NameDesignationYear
SWAPNIL JATINBHAI SHAHManaging Director2025
Sanjay MajmudarChairman (Non-Executive)2025
Hemanshu Nitinchandra PandyaNon Executive Director2025
Jitendra Babulal SanghviIndependent Director2025
Chetan Bipinchandra ShahWhole Time Director & Chief Operating Officer2025
Deval Rajnikant ShahWhole Time Director & Chief Financial Officer2025
Ashokkumar Vijaysinh BarotNon Executive Director2025
ARPIT DEEPAKKUMAR SHAHNon Executive Director2025
Naresh Bansilal ShahIndependent Director2025
Manjula Devi ShroffIndependent Director2025
Kalpit Rajesh GandhiIndependent Director2025
Udayan ChoksiIndependent Director2025
Segments — Geography
RegionRevenueShare
Within India₹22 Cr56.7%
Outside India₹17 Cr43.3%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10544646
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202400069287367
202400065233308
2024000000
Insider / Designated-Person Trades

30 recent disclosure(s)

Dhruvalben Vishal ShahAcquisition · 350
RENOSEN PHARMACEUTICALS PRIVATE LIMITEDRevoke · 4,00,000
Espee Therapeutics LLPPledge · 4,00,000
RENOSEN PHARMACEUTICALS PRIVATE LIMITEDAcquisition · 6,000
RENOSEN PHARMACEUTICALS PRIVATE LIMITEDAcquisition · 4,000
Dhruvalben Vishal ShahAcquisition · 150
Substantial Acquisitions (SAST)

4 disclosure(s)

Market31/12/2025 · 6,000
Market17/12/2025 · 4,000
Market28/07/2025 · 3,000
Market26/05/2025 · 4,000
Company Information
Incorporated2017
ChairmanSanjay Majmudar
AuditorPankaj R Shah & Associates
Investor Email[email protected]
🌐 www.senorespharma.com ↗

📍 #.1101-1103 11th Flr South Twr, Ambali Bopal Road, Ahmedabad, Gujarat, 380054

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Sejal Glass LimitedSungarner Energies Ltd.Sellowrap Industries Ltd.SEL Manufacturing Co Ltd.Semac Construction Ltd.Senco Gold LimitedSEPC LimitedService Care LimitedServotech Ren Pow Sys Ltd.Seshasayee Paper & BoardsSetco Automotive Ltd.Standard Engng Tcnlgy Ltd.All “S” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search